MedTrace Logo

Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal

NCT04906941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2026-01-05

No results posted yet for this study

Summary

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Conditions

  • White Matter Disease

Interventions

DEVICE

MRI

SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment. \* Sense 2 \* 2: 9min33s

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-21
Primary Completion
2023-07-19
Completion
2023-07-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906941 on ClinicalTrials.gov